Microscan Celebrates 20 Years of Data Matrix Codes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Microscan Celebrates 20 Years of Data Matrix Codes


Microscan, a manufacturer of precision data acquisition and control solutions for automation and OEM applications, celebrates the 20th anniversary of the two-dimensional (2D) data matrix code. Since the invention of data matrix in 1994 by International Data Matrix, Inc. (I.D. Matrix), 2D data matric codes have played an important role in track and trace in manufacturing and production, which includes pharmaceutical products.

A single data matrix code can hold thousands of characters. Its benefits include the compact size, data-carrying capacity and generous reading tolerance. According to Microscan, data matrix can be read at lower contrast ratios than most barcode symbologies, which is advantageous in environments where codes may be obscured and in cases where the code is directly applied to metal and other reflective surfaces through various marking methods.

Data Matrix codes with scratches, tears, or stains can be successfully read without data loss, even if more than 20% of the symbol is damaged, making it the code of choice in data tracking and traceability regulations and standards, such as the FDA and EU regulations for packaging of pharmaceutical products.  

Source: Microscan

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here